Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination

Robert I. Nicholson, Iain R. Hutcheson, Janice M. Knowlden, Helen E. Jones, Maureen E. Harper, Nicola Jordan, Steve E. Hiscox, Denise Barrow, Julia M.W. Gee, Mina Bissell, Myles Brown, James Ingle, Jeffrey Green, Carlos Arteaga, Matthew Ellis, Richard Santen

Research output: Contribution to journalArticle

106 Scopus citations

Abstract

An increasing body of evidence demonstrates that growth factor networks are highly interactive with estrogen receptor signaling in the control of breast cancer growth. As such, tumor responses to antiestrogens are likely to be a composite of the estrogen receptor and growth factor-inhibitory activity of these agents, with alterations/aberrations in growth factor signaling providing a mechanism for the development of antiestrogen resistance. In this light, the current article focuses on illustrating the relationship between growth factor signaling and antiestrogen failure in our in-house tumor models of breast cancer and describing how we are now beginning to successfully target growth factor activity to improve the effects of antiestrogen drugs and to block aggressive disease progression.

Original languageEnglish (US)
Pages (from-to)346s-354s
JournalClinical Cancer Research
Volume10
Issue number1 II
DOIs
StatePublished - Jan 28 2004

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination'. Together they form a unique fingerprint.

  • Cite this

    Nicholson, R. I., Hutcheson, I. R., Knowlden, J. M., Jones, H. E., Harper, M. E., Jordan, N., Hiscox, S. E., Barrow, D., Gee, J. M. W., Bissell, M., Brown, M., Ingle, J., Green, J., Arteaga, C., Ellis, M., & Santen, R. (2004). Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination. Clinical Cancer Research, 10(1 II), 346s-354s. https://doi.org/10.1158/1078-0432.CCR-031206